Chronic Lymphocytic Leukemia | Topics

ELEVATE-RR: Efficacy Data
May 24, 2022

Experts discuss efficacy data from the ELEVATE-RR trial on the Bruton tyrosine kinase inhibitors acalabrutinib vs ibrutinib.

Patient Characteristics in ELEVATE-RR
May 24, 2022

Dr Bishop comments on the characteristics of the patients with CLL who were enrolled in the ELEVATE-RR trial.

Ibrutinib Plus Rituximab Yields Superior Survival Vs FCR in CLL, Regardless of IGHV Status
May 18, 2022

Patients with untreated, IGHV-mutated and -unmutated chronic lymphocytic leukemia experienced better overall survival and progression-free survival with ibrutinib and rituximab compared with fludarabine, cyclophosphamide, and rituximab.

ELEVATE-RR Study Overview
May 16, 2022

Dr Bishop reviews the ELEVATE-RR trial enrollment strategy.

Introduction and CLL Background
May 16, 2022

Michael R. Bishop, MD, introduces the 2021 Journal of Clinical Oncology publication, “Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial” and invites Bruce B. Bank, MD, to comment on the typical patients with chronic lymphocytic leukemia (CLL) he sees in his clinical practice.

First-Line Ibrutinib Discontinuation Due to Progression Significantly Higher in CLL With Vs Without Deletion 17p
May 11, 2022

Patients with treatment-naïve chronic lymphocytic leukemia with the presence of deletion 17p who received treatment with ibrutinib in the first line were more likely to have poor survival and to discontinue treatment due to progression vs those without.

Ublituximab/Umbralisib Applications Voluntary Withdrawn for CLL and SLL Indications
April 18, 2022

TG Therapeutics made the decision to voluntarily pull the biologics license application and supplemental new drug application for ublituximab/umbralisib in patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

Paul Barr, MD, Highlights Robust 8-Year Follow-Up Data of Frontline Ibrutinib in Older Patients With CLL
April 15, 2022

In an interview with CancerNetwork®, Paul Barr, MD, discusses 8-year follow-up data from the phase 3 RESONATE-2 trial, assessing first-line ibrutinib in patients 65 years of age or older with chronic lymphocytic leukemia.

Ibrutinib Plus Venetoclax at a Fixed Duration Yields Positive PFS in CLL/SLL
April 12, 2022

Ibrutinib plus venetoclax given at a fixed duration yielded favorable progression-free survival in patients with previously untreated, high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma.

Addition of CART-19 to Ibrutinib Yields Deep, Durable Remissions in CLL
April 08, 2022

Longer and more durable remissions were identified with the addition of CART-19 to ibrutinib for patients with chronic lymphocytic leukemia.